Get the Stockscreener App
16.28
0.61%
-0.10
After Hours:
16.50
0.22
+1.35%
Denali Therapeutics Inc stock is traded at $16.28, with a volume of 1.23M.
It is down -0.61% in the last 24 hours and up +12.12% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$16.38
Open:
$16.25
24h Volume:
1.23M
Relative Volume:
0.64
Market Cap:
$2.38B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-5.7123
EPS:
-2.85
Net Cash Flow:
$-402.10M
1W Performance:
+2.01%
1M Performance:
+12.12%
6M Performance:
-2.22%
1Y Performance:
-37.29%
1-Day Range:
$15.90
$16.45
1-Week Range:
$15.90
$17.02
52-Week Range:
$10.57
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
16.28 | 2.39B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Why analysts remain bullish on Denali Therapeutics Inc. stockPrice Action & Growth Focused Investment Plans - newser.com
Comparing Denali Therapeutics Inc. in custom built stock radarsPrice Action & Daily Oversold Stock Bounce Ideas - newser.com
Can Denali Therapeutics Inc. (4DN) stock test all time highsJuly 2025 Final Week & Expert Approved Trade Ideas - newser.com
Is Denali Therapeutics Inc. stock a contrarian buyStop Loss & Growth Focused Investment Plans - newser.com
Pier Capital LLC Sells 20,708 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics Inc. $DNLI Shares Purchased by State of New Jersey Common Pension Fund D - MarketBeat
Published on: 2025-11-02 03:18:16 - newser.com
Will Denali Therapeutics Inc. (4DN) stock enhance shareholder valueStock Surge & Free Safe Entry Trade Signal Reports - newser.com
Detecting price anomalies in Denali Therapeutics Inc. with AIPortfolio Risk Report & Free Fast Gain Swing Trade Alerts - newser.com
Is Denali Therapeutics Inc. stock ready for a breakoutGDP Growth & Consistent Profit Trade Alerts - newser.com
Is Denali Therapeutics Inc. stock a top momentum play2025 Market Overview & AI Forecast for Swing Trade Picks - newser.com
Will Denali Therapeutics Inc. (4DN) stock outperform small cap peers2025 Dividend Review & Stepwise Trade Execution Plans - newser.com
Is Denali Therapeutics Inc. stock a dividend growth opportunityQuarterly Portfolio Review & Risk Controlled Daily Plans - newser.com
Savvy Advisors Inc. Invests $1.37 Million in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics Inc expected to post a loss of 75 cents a shareEarnings Preview - TradingView
Applying sector rotation models to Denali Therapeutics Inc.Fed Meeting & Safe Capital Growth Stock Tips - newser.com
Does Denali Therapeutics Inc. qualify in momentum factor screeningJuly 2025 Price Swings & Expert Curated Trade Setups - newser.com
Can Denali Therapeutics Inc. (4DN) stock resist broad market declinesShort Setup & Verified Swing Trading Watchlists - newser.com
Will Denali Therapeutics Inc. stock rally after Fed decisionsJuly 2025 Pullbacks & Low Volatility Stock Suggestions - newser.com
How Denali Therapeutics Inc. (4DN) stock gains from tech spendingEarnings Risk Report & Low Risk Profit Maximizing Plans - newser.com
Published on: 2025-10-30 23:48:28 - newser.com
Denali Therapeutics (DNLI) to Release Quarterly Earnings on Wednesday - MarketBeat
Published on: 2025-10-29 04:42:36 - newser.com
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):